Yost Capital Management LP Makes New Investment in Maravai LifeSciences Holdings, Inc. $MRVI

Yost Capital Management LP bought a new position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 126,056 shares of the company’s stock, valued at approximately $410,000. Maravai LifeSciences makes up about 0.6% of Yost Capital Management LP’s portfolio, making the stock its 13th largest holding.

A number of other hedge funds have also added to or reduced their stakes in MRVI. Monaco Asset Management SAM grew its stake in Maravai LifeSciences by 315.0% in the 3rd quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock worth $10,494,000 after acquiring an additional 2,775,372 shares in the last quarter. General American Investors Co. Inc. boosted its stake in shares of Maravai LifeSciences by 1,062.2% during the fourth quarter. General American Investors Co. Inc. now owns 1,585,316 shares of the company’s stock valued at $5,152,000 after purchasing an additional 1,448,907 shares in the last quarter. First Eagle Investment Management LLC boosted its stake in shares of Maravai LifeSciences by 299.0% during the fourth quarter. First Eagle Investment Management LLC now owns 1,799,336 shares of the company’s stock valued at $5,848,000 after purchasing an additional 1,348,405 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of Maravai LifeSciences by 52.3% during the fourth quarter. Marshall Wace LLP now owns 2,000,278 shares of the company’s stock valued at $6,501,000 after purchasing an additional 687,253 shares in the last quarter. Finally, Tejara Capital Ltd boosted its stake in shares of Maravai LifeSciences by 23.1% during the fourth quarter. Tejara Capital Ltd now owns 3,020,209 shares of the company’s stock valued at $9,816,000 after purchasing an additional 566,768 shares in the last quarter. 50.25% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on MRVI. UBS Group reiterated a “reduce” rating on shares of Maravai LifeSciences in a research note on Wednesday, June 3rd. Wells Fargo & Company increased their price objective on shares of Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a research note on Friday, May 8th. Wall Street Zen upgraded shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Weiss Ratings upgraded shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $6.00 price objective on shares of Maravai LifeSciences in a research note on Friday, May 8th. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $5.50.

Insider Activity

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total value of $126,500.00. Following the completion of the transaction, the general counsel owned 360,767 shares of the company’s stock, valued at approximately $1,825,481.02. This trade represents a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.49% of the company’s stock.

Maravai LifeSciences Stock Performance

NASDAQ MRVI opened at $4.98 on Monday. The company has a fifty day simple moving average of $4.06 and a two-hundred day simple moving average of $3.65. The stock has a market cap of $1.29 billion, a P/E ratio of -7.01 and a beta of 0.71. Maravai LifeSciences Holdings, Inc. has a 12-month low of $1.99 and a 12-month high of $5.30. The company has a current ratio of 5.91, a quick ratio of 4.96 and a debt-to-equity ratio of 0.72.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. The business had revenue of $65.84 million during the quarter, compared to analysts’ expectations of $53.00 million. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. On average, analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current year.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.